The rapid development of COVID-19 vaccines did appear to defy the traditional “fast, good, cheap — pick two” paradigm, largely due to unprecedented global collaboration, government subsidies, and existing research infrastructure. Emergency Use Authorizations (EUAs), overlapping clinical trial phases, and…   Read more»